Favorable glycemic response after pancreatoduodenectomy in both patients with pancreatic cancer and patients with non-pancreatic cancer. Issue 18 (May 2018)

• Record Type: Journal Article
• Authors: Sohn, Seo Young; Lee, Eun Kyung; Han, Sung-Sik; Lee, You Jin; Hwangbo, Yul; Kang, Young Hwa; Lee, Seung Duk; Kim, Seong Hoon; Woo, Sang Myung; Lee, Woo Jin; Hong, Eun Kyung; Park, Sang-Jae
• Other Names: Saisho. Yoshifumi section editor.
• Is Part Of: Medicine. Volume 97:Issue 18(2018)
• Publication Date: 2018-05
• Subjects: diabetes mellitus -- glucose metabolism -- pancreatic cancer -- pancreatoduodenectomy -- periampullary cancer; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000010590
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Diabetes mellitus (DM) is prevalent in patients with pancreatic cancer and tends to improve after tumor resection. However, the glycemic response of non-pancreatic cancer patients after surgery has not been examined in detail. We aimed to investigate the changes in glucose metabolism in patients with pancreatic cancer or non-pancreatic cancer after pancreatoduodenectomy (PD). We prospectively enrolled 48 patients with pancreatic cancer and 56 patients with non-pancreatic cancer, who underwent PD. Glucose metabolism was assessed with fasting glucose, glycated hemoglobin (HbA1c), plasma C-peptide and insulin, quantitative insulin check index (QUICKI), and a homeostatic model assessment of insulin resistance (HOMA-IR) and β cell (HOMA-β) before surgery and 6 months after surgery. Patients were divided into 2 groups: "improved" and "worsened" postoperative glycemic response, according to the changes in HbA1c and anti-diabetic medication. New-onset DM was defined as diagnosis of DM ⩽ 2 years before PD, and cases with DM diagnosis >2 years preceding PD were described as long-standing DM. After PD, insulin resistance (IR), as measured by insulin, HOMA-IR and QUICKI, improved significantly, although C-peptide and HOMA-β decreased. At 6 months after PD, new-onset DM patients showed improved glycemic control in both pancreatic cancer patients (75%) and non-pancreatic cancer patients (63%). Multivariate analysis showed that long-standing DM was a significant predictor for worsening glucose control (odds ratio = 4.01, P = .017). Favorable glycemic control was frequently observed in both pancreatic cancer and non-pancreatic cancer after PD. PD seems to contribute improved glucose control through the decreased IR. New-onset DM showed better glycemic control than long-standing DM.